ArticleOncogene2026

Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8⁺ T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy.

Congcong Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.